YSYang Song

Yang Song

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yang Song has a total of 93 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    KRAS-driven protein disulfide isomerase family A member 6 expression suppresses PRKR-like endoplasmic reticulum kinase-mediated immunogenic cell death to desensitise pancreatic ductal adenocarcinoma to immune checkpoint blockers

    by Ronglin Wang, Junqiang Li, Danjie Su, Jing Yang, Peixiang Ma, Lei Hua, Jing Luo, Jingyi Liu, Rui Yang, Liang Zhang, et al.

    Background: Pancreatic ductal adenocarcinoma (PDAC) is characterised by a dismal prognosis and insensitivity to immune checkpoint blockers (ICBs); however, the underlying mechanism remains elusive. Objective: This study aimed to identify tumour cell-intrinsic regulators that promote immune evasion and ICB resistance in PDAC. Design: Multi-omics analysis and clinical cohort studies identified protein disulfide isomerase family A member 6 (PDIA6) as a regulator of the immune microenvironment. Flow cytometry, multiplex immunohistochemistry, electron microscopy and Glutathione S-Transferase (GST) pulldown assays confirmed that PDIA6 repressed PRKR-like endoplasmic reticulum kinase (PERK) activation and immunogenic cell death (ICD). Chromatin immunoprecipitation confirmed that KRAS G12D and YY1 modulated PDIA6 transcription. LSL- Kras G12D/+ ;LSL- Trp53 R172H/+ ; Pdx-1- Cre (KPC) mouse models showed that PDIA6 inhibition improved ICB response. Results: Multi-omics screening identified PDIA6 as a biomarker of CD8 + T-cell paucity and poor prognosis in patients with PDAC. High PDIA6 levels predicted poor ICB response in the PDAC cohorts. PDIA6 inhibition reprogrammed the immunosuppressive tumour microenvironment and hindered mouse PDAC growth in the presence of CD8 + T-cell, which is attributed to enhanced ICD. PDIA6 interacted with cysteine 453 of PERK, abrogating the disulphide bond-mediated dimerisation and activation of PERK, an ICD inducer. Oncogenic KRAS G12D potently upregulated PDIA6 via YY1-mediated transcriptional activation. We identified a small-molecule inhibitor of PDIA6, PACMA31, and demonstrated that targeting PDIA6 with PACMA31 improved ICB efficacy in a PDAC mouse model with KRAS mutations. Conclusions: PDIA6, driven by KRAS G12D , alleviates ICD and promotes immune evasion, functioning as a predictive biomarker to screen ICB-sensitive patients and a therapeutic target to improve ICB efficacy in PDAC with KRAS mutations.


  • Open Access

    GIPC1 Restrains the Progression and Chemoresistance of Colorectal Cancer by Regulating TTC7B/mTOR/NF-κB Axis

    by Dongxue Gan, Cheng Yang, Xiangjing Shen, Jingjie Shi, Ronglin Wang, Liaoliao Zhu, Hong Li, Jing Luo, Ting Zhao, Junqiang Li, et al.

    Colorectal cancer (CRC) remains a leading cause of cancer-related mortality, highlighting the need for a deeper understanding of its molecular mechanisms to drive the development of novel therapeutic approaches. In this study, the findings indicated a significant reduction in PDZ Domain Containing Family Member 1 (GIPC1) expression in CRC tissues, which correlated with poor prognosis in patients with CRC at pathological stages T1 and T2. GIPC1 acted as a tumor suppressor gene that inhibited CRC cell proliferation, colony formation, migration, and invasion. Additionally, it enhanced CRC cell sensitivity to first-line chemotherapies such as 5-fluorouracil (5-FU), oxaliplatin (OXA), and irinotecan (CPT-11). Mechanistically, GIPC1 reduced the ubiquitination level of tetratricopeptide repeat domain 7B (TTC7B) by downregulating the E3 ubiquitin ligase TRIM21, thereby stabilizing TTC7B's expression and inhibiting the downstream mTOR/NF-κB signaling cascade. Moreover, in vivo studies confirmed the inhibitory role of GIPC1 in CRC growth and found that GIPC1-loaded lipid nanoparticles (GIPC1-LNPs) combined with 5-FU treatment had a more significant antitumor effect. In conclusion, this study reveals the GIPC1/TRIM21/TTC7B/mTOR/NF-κB tumor-suppressive axis in CRC and highlights the potential of GIPC1 for early diagnosis and overcoming chemoresistance in CRC patients.


  • Open Access

    CMKLR1/PKA signaling reinforces sonic hedgehog pathway to promote medulloblastoma pathogenesis

    by Shan Wang, Tongtong Jiang, Tao Wang, Zhiwei Yang, Ting Wang, Xiao Zhang, Xingchun Gou, Lintao Jia, Liang Wang, Yang Song

    Aberrant Hedgehog signaling is a key driver of malignancies like medulloblastoma (MB), the most common pediatric brain tumor originating from cerebellar granule neuron progenitors with largely uncharacterized mechanisms. We found here that the G protein-coupled receptor, chemokine-like receptor 1 (CMKLR1), is upregulated and correlates with the development of Sonic Hedgehog (SHH)-subtype MB. SHH and the downstream transcription factor Gli2 license the expression of CMKLR1, which promotes the growth and migration of cells by activating Gα(i)βγ and subsequently the PI3K/Akt signal pathway. SHH/Gli also transcriptionally represses Regulator of G Protein Signaling 16 (RGS16), a known suppressor of Gα(i). Meanwhile, CMKLR1/Gα(i) signaling inactivates protein kinase A (PKA), reduces PKA-catalyzed phosphorylation of Gli2, and circumvents its proteasomal degradation, thus forming a feedback circuit in medulloblastoma cells. Consistently, CMKLR1 ablation suppresses the in vivo development of SHH subtype MB, which is counteracted by further silencing of the PKA catalytic subunit. These findings provide novel insights into the oncogenic network of Hedgehog pathway-driven cancer.


  • Open Access

    The type I collagen paradox in PDAC progression: microenvironmental protector turned tumor accomplice

    by Qian Li, Cheng Yang, Junqiang Li, Ronglin Wang, Jie Min, Yang Song, Haichuan Su

    Type I collagen (Collagen I, Col I), a principal component of the tumor extracellular matrix (ECM) that accounts for 80% of total ECM collagen, has emerged as a crucial factor in tumor biology. Recent research has found that Col I has influenced tumor growth, invasion, migration, and prognosis by forming a physical barrier and interacting with components in the tumor microenvironment (TME). Pancreatic ductal adenocarcinoma (PDAC) is characterized by a prominent stromal microenvironment with remarkable cellular and spatial heterogeneity, which significantly impacts the biology of the disease and its resistance to treatment. As research on the influence of ECM on tumor behavior progresses, the role of Col I in tumor occurrence and development has also been gradually expounded. Unlike the pro-tumorigenic role caused by excessive deposition in other cancers, PDAC features a dense stroma with spatial heterogeneity, where Col I deposition exhibits paradoxical pro- and anti-tumor effects: Cancer-associated fibroblasts secrete heterotrimeric Col I (α1/α1/α2), which initially suppresses tumor growth by recruiting M1 macrophages, while tumor cells produce homotrimeric Col I (α1/α1/α1, 2–3% of total Col I) to promote immune evasion via CXCL5 secretion and CD8+ T cell reduction. Mechanistically, Col I activates TGF-β/SMAD3 signaling to drive epithelial–mesenchymal transition (EMT) and enhances matrix stiffness, increasing tumor cell migration by 60–80% in 3D cell culture models. Thus, understanding the complex interactions between Col I and other microenvironmental components may enhance its anti-tumor action while suppressing its pro-tumor activity, potentially improving PDAC patients’ survival. In this review, we discuss the current research progress regarding the function of Col I in PDAC tumors and summarize its contributions to PDAC progression, thus providing a basis for follow-up research and potential targets for cancer treatment.


  • Open Access

    NUCKS1 promotes invasion and metastasis of colorectal cancer by stabilizing HDAC2 and activating AKT

    by Liaoliao Zhu, Ting Zhao, Haichuan Su, Junqiang Li, Xiangjing Shen, Liang Zhang, Jun Chen, Yang Song

    Nuclear ubiquitous casein and cyclin-dependent kinase substrate 1 (NUCKS1) functions as an oncogene in colorectal cancer (CRC), promotes the progression of CRC, and is associated with poor prognosis in patients. Studies have found that NUCKS1 promotes tumor cell metastasis, yet its role in CRC invasion and metastasis remains unclear. Our findings revealed higher NUCKS1 expression in metastatic CRC compared to non-metastatic samples. Upregulation of NUCKS1 expression promoted the migration and invasion of CRC cells, while knockdown of NUCKS1 significantly inhibited the migration and invasion of CRC cells. Mechanistically, NUCKS1 was initially found to upregulate HDAC2 expression by inhibiting the lysosomal pathway, activating AKT, and thus promoting CRC invasion and metastasis. Moreover, HDAC2 inhibitor Santacruzamate A or AKT inhibitor LY294002 rescued the migration and invasion of CRC cells caused by NUCKS1 overexpression. In vivo, by injecting CRC cells into the tail vein of a nude mouse model, we found that overexpression of NUCKS1-induced lung and liver metastasis was suppressed by HDAC2 knockdown or intraperitoneal administration of the HDAC2 inhibitor Santacruzamate A. Meanwhile, AKT inhibitor LY294002 significantly inhibited lung and liver metastasis caused by overexpression of HDAC2. The expression levels of NUCKS1, HDAC2, and phosphorylated AKT were significantly positively correlated in human CRC tissues. These findings suggest that NUCKS1 contributes to CRC invasion and metastasis by stabilizing HDAC2 and activating AKT, highlighting NUCKS1 and HDAC2 as potential therapeutic targets for CRC.


  • Ran drives pancreatic cancer metastasis by activating the osteopontin-PI3K/AKT-androgen receptor signaling cascade

    by Lin Deng, Jingyi Ren, Dong Liu, Hong Li, Guang Yang, Kairui Wang, Yang Song, Haichuan Su


  • Open Access

    Pan-cancer analysis of the prognostic and immunological role of hippo-YAP signaling pathway

    by Jing Yang, Cheng Yang, Guang Yang, Ronglin Wang, Junqiang Li, Yang Song

    The Hippo-Yes-associated protein (Hippo-YAP) signaling pathway, a conserved pathway that regulates organ size, participates in tumor progression. However, there are few comprehensive analyses of tumor prognosis and immunity. In the present study, TCGA, GTEx, GEO, TIMER2, STRING, GSCA, ImmuCellAI, and other bioinformatics tools were used to reveal the involvement of the Hippo-YAP signaling pathway in the prognosis and immunity of pan-cancers. The obtained results showed that mRNA expression differences of Hippo-YAP pathway genes between normal samples and tumor samples in pan-cancers and some genes (such as TEAD4, MAP4K4, and STK3) might affect the prognosis of patients with skin cutaneous melanoma (SKCM) and pancreatic adenocarcinoma (PAAD). Furthermore, mutation and methylation of the Hippo-YAP signaling pathway genes in normal and primary tumor tissues differ in various cancers (KIRP, BRCA). Additionally, the relationship between the tumor microenvironment, molecular pathways, and the Hippo-YAP pathway indicated that it might lead to a suppressive immune microenvironment that affects the efficacy of immunotherapy. This is a pan-cancer overview of the Hippo-YAP signaling pathway genes, which explores the aberrant expression or mutation of this pathway that regulates the tumor microenvironment and immunotherapy.


  • Top Cited Papers
    Open Access

    Advances and clinical challenges of mesenchymal stem cell therapy

    by Ruiyan Mei, Zhuo Wan, Cheng Yang, Xiangjing Shen, Ronglin Wang, Haihua Zhang, Rui Yang, Junqiang Li, Yang Song, Haichuan Su

    In recent years, cell therapy has provided desirable properties for promising new drugs. Mesenchymal stem cells are promising candidates for developing genetic engineering and drug delivery strategies due to their inherent properties, including immune regulation, homing ability and tumor tropism. The therapeutic potential of mesenchymal stem cells is being investigated for cancer therapy, inflammatory and fibrotic diseases, among others. Mesenchymal stem cells are attractive cellular carriers for synthetic nanoparticles for drug delivery due to their inherent homing ability. In this review, we comprehensively discuss the various genetic and non-genetic strategies of mesenchymal stem cells and their derivatives in drug delivery, tumor therapy, immune regulation, tissue regeneration and other fields. In addition, we discuss the current limitations of stem cell therapy and the challenges in clinical translation, aiming to identify important development areas and potential future directions.


  • CIRBP Promotes Colorectal Cancer Progression by Regulating SAM68/p38 Signaling Pathway

    by Peixiang Ma, Jie Min, Junqiang Li, Ronglin Wang, Bo Shi, Rui Yang, Cheng Yang, Xin Sun, Ting Zhao, Yang Song, et al.

    Background: Colorectal cancer (CRC) is a type of malignant gastrointestinal cancer with a poor prognosis. Cold-inducible RNA binding protein (CIRBP) is a novel proto-oncogene that promotes the development of certain malignancies. Nevertheless, the relevance of CIRBP in CRC and the molecular processes behind it are still unknown. This study aimed to explore the molecular mechanism and biological function of CIRBP in CRC. Methods: In this study, CIRBP protein expression in CRC samples and control samples was analyzed by Immunohistochemistry (IHC) analysis. The relationship of CIRBP expression and disease-free survival (DFS) and overall survival (OS) was assessed in CRC patients. Immunofluorescence (IF) assay, western blotting, and quantitative real-time polymerase chain reaction (qRT-PCR) were used to analyze the expression or connection of CIRBP and Src associated in mitosis of 68 kDa (sarcoma-associated in mitosis of 68 kDa (SAM68)). CRC proliferation was investigated by cell-counting-kit-8 (CCK8) assay, colony formation assay, flow cytometric analysis, and animal studies. Migration and invasion were investigated by transwell assay. RNA sequencing and Common-immunoprecipitation (Co-IP) with protein mass spectrometry were used to investigate the underlying pathways of CIRBP in CRC. Results: The findings demonstrated that CIRBP was abundant in CRC tissues, and that individuals with significant CIRBP expression had a poor prognosis. In vitro and in vivo, CIRBP/SAM68 knockdown or overexpression reduced or accelerated CRC proliferation, invasion and migration, respectively. Moreover, overexpression of SAM68 rescued the influence of CIRBP silencing on the malignant phenotype. Mechanistically, CIRBP directly bound to and increased the expression of SAM68. This mediated the excessive activation of the p38 signaling pathway. Overall, this study showed that CIRBP was an upregulated CRC-related oncogene. Conclusion: Higher CIRBP expression may be related to decreased prognostic factors for overall survival (OS) and disease-free survival (DFS). CIRBP was found to enhance CRC development via the SAM68/p38 signal transduction pathway.

  • Open Access

    Machine learning-based integration develops a metabolism-derived consensus model for improving immunotherapy in pancreatic cancer

    by Yongdong Guo, Ronglin Wang, Jingjie Shi, Cheng Yang, Peixiang Ma, Jie Min, Ting Zhao, Lei Hua, Yang Song, Junqiang Li, et al.

    Background Pancreatic cancer (PAC) is one of the most malignant cancer types and immunotherapy has emerged as a promising treatment option. PAC cells undergo metabolic reprogramming, which is thought to modulate the tumor microenvironment (TME) and affect immunotherapy outcomes. However, the metabolic landscape of PAC and its association with the TME remains largely unexplored. Methods We characterized the metabolic landscape of PAC based on 112 metabolic pathways and constructed a novel metabolism-related signature (MBS) using data from 1,188 patients with PAC. We evaluated the predictive performance of MBS for immunotherapy outcomes in 11 immunotherapy cohorts from both bulk-RNA and single-cell perspectives. We validated our results using immunohistochemistry, western blotting, colony-formation assays, and an in-house cohort. Results MBS was found to be negatively associated with antitumor immunity, while positively correlated with cancer stemness, intratumoral heterogeneity, and immune resistant pathways. Notably, MBS outperformed other acknowledged signatures for predicting immunotherapy response in multiple immunotherapy cohorts. Additionally, MBS was a powerful and robust biomarker for predicting prognosis compared with 66 published signatures. Further, we identified dasatinib and epothilone B as potential therapeutic options for MBS-high patients, which were validated through experiments. Conclusions Our study provides insights into the mechanisms of immunotherapy resistance in PAC and introduces MBS as a robust metabolism-based indicator for predicting response to immunotherapy and prognosis in patients with PAC. These findings have significant implications for the development of personalized treatment strategies in patients with PAC and highlight the importance of considering metabolic pathways and immune infiltration in TME regulation.